Results are visible almost immediately, with full results settling in within a few weeks
ATTAIN-2 (NCT05872620) was a Phase III, 72-week, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of various doses of orforglipron with placebo in adults with obesity or overweight and type 2 diabetes
Tirzepatide: A dual GLP-1 and GIP receptor agonist that enhances insulin secretion, reduces hunger, and improves metabolic function, marketed under brand names like Mounjaro and Zepbound
Vitamin B12 Injection Benefits Boosts metabolism Prevents anaemia Improves brain health Prevents depression Prevents osteoporosis Promotes healthy hair, nails, and skin Prevents macular degeneration Boosts energy levels Initial loading dose 2000mg per week for 4 weeks, after 2000mg per month
F., Tedrow, U